were rendered physically dependent on phenobarbital by phenobarbital admixed foods. Barbital, phenobarbital, ethanol, diazepam, nitrazepam, meprobamate, methaqualone, chlorpromazine, diphenylhydantoin, mephenesin, reserpine and clonidine were cross-administered to evaluate the mode of suppression of withdrawal signs and cross-physical dependence liability. The drugs were administered several times during the period from 17-18 hr (when withdrawal signs began to appear) to about 48 hr after the withdrawal of phenobarbital. From the mode of suppression and severity of relapsed withdrawal signs, these drugs were classified into the following 3 types: Type I: drugs suppressing withdrawal signs of phenobarbital (WSP) almost completely and followed by the relapse of severe WSP. Type II-a: drugs suppressing WSP partially and followed by the relapse of moderate WSP. Type II-b: drugs suppressing WSP partially and followed by the relapse of only mild or practically no signs. Type III (III-a and -b): drugs practically failing to suppress or rather aggravate WSP. Consequently, we found that it was possible to evaluate precisely the cross-physical dependence on sedative hypnotics by means of investigation for the method of suppression of WSP and the relapse of such signs upon their withdrawal.
In the previous papers (1 , 2), we reported a correlation between physical dependence liability to phenobarbital (PhB) or barbital in rats fed on a food containing such a drug (barbiturate-dependence model) and its con centration in the brain and blood capable of maintaining the dependence.
In the same papers, we described that systemic muscle rigidity, fascicular twitching, hyperirritability, ataxia, hyperkinesia, clonic-tonic convulsion and even grand mal-type convulsion appeared during the period from 17 or 18 hr to 48 hr after the withdrawal.
When the drug had disappeared almost completely in the blood, some rats died immediately after the spon taneous convulsion (1). These kinds of withdrawal signs, time course of their appearance and their duration were similar to those not only in man (3), but also similar to those in large animals such as dogs (4) and monkeys (5). We considered that the rat was useful as a model for physical de pendence on sedative-hypnotics. There are reports of cross-physical dependence liability to sedative-hypnotics in dogs (6), monkeys (7), rats (8) and mice (9-11).
However, the methods for the evaluation of such physical dependence liability in small animals and their usefulness have not yet been demonstrated sufficiently (12, 13) . In their studies, Goldstein (10) and Belknap et al. (11) investigated the effects of cross-administered drugs on convulsive seizure using the alcohol or PhB-deperidence model in mice. Our aforementioned model is characterized not only by less variations in withdrawal signs, but also by the appearance of convulsions in rats. In general, the drugs cross-administered showed different manner of actions on the withdrawal signs. In mice, however, the duration of withdrawal signs is short, and it becomes not possible to admin ister the test drugs sufficiently enough to discriminate the appearent inhibition of withdrawal signs from cross-physical de pendence liability (14) . Clinically, there are many patients dependent on alcohol or on sedative-hypnotics treated with substitution drugs for a week or so. The WHO Technical Reports (12, 13) recommend the daily cross-administration of test drug for 6 days as the authorized method for the evaluation of cross-physical dependence liability to sedative hypnotics.
To evaluate cross-physical dependence of a few kinds of centrally acting drugs, in this study, drugs were examined both for in hibition of PhB withdrawal signs and for maintenance of physical dependence on it.
The results were compared with the findings in other species of animals. Furthermore, changes in the body weight of rats during and after the cross-administration period were examined for usefulness as an index for the evaluation of cross-physical de pendence liability to sedative-hypnotics.
Materials and Methods
Five to six-week old Sprague-Dawley (S.D.) rats were rendered physically de pendent on phenobarbital (PhB) by PhB admixed food of gradedly increasing dosage schedule (1). PhB-admixed food was gradedly increased from the initial level of 0.5 and 1 mg/g food to the final level of 4 mg/g food over 39 days. At 5:00 P.M. on the final dosing day, the PhB-admixed food was replaced with a drug-free normal food (natural withdrawal). At 17-18 hr of with drawal, the rats had already begun to exhibit moderate to severe withdrawal signs (1) such as clonic convulsion, weight loss, etc. At 24 to 48 hr of withdrawal, they exhibited severe withdrawal signs: clonic-tonic con vulsion and grand mal-type convulsion. The rats were cross-administered with the test drugs several times as a rule from 10:00 A.M. the following morning (17 to 18 hr of PhB withdrawal) to 48 hr of PhB withdrawal when almost all natural withdrawal signs had already diminished.
Intervals of cross administration with the test drugs were determined according to speeds of me tabolism, the state of inhibition of withdrawal signs, the duration of the inhibition, and also by observing the general behaviors of the rats. Such doses of the test drugs as proven in a preliminary study to be capable of maintaining moderate CNS depression but not to be overdoses in terms of general behaviors were chosen for the cross-adminis tration. After the final cross-administration, the rats continued to be withdrawn from the test drugs and were examined for the relapse of PhB withdrawal signs or the maintenance of PhB dependence.
The rats were weighed, and their food consumptions were measured at each cross administration and also after the end of the cross-administration at appropriate intervals.
1. Dose-related inhibition of withdrawal signs using changes in body weight as an index: The rats maintained PhB-dependent with 4 mg PhB/g food (maintenance dose: average 200 mg/kg/day) were cross-adminis tered orally with 5, 10, 20 or 40 mg/kg of PhB, 6 times at 6-hr intervals from 18 hr of withdrawal onward. PhB was suspended in carboxymethyl cellullose-Na (CIVIC) in con centrations at which the respective doses were adjusted to a volume of 0.5 ml/100 g of body weight. Phenobarbital was administered 6 times from 17 hr to 48 hr after removal of phenobarbital-admixed food. Subsequent relapse of body weight loss and withdrawal signs were observed following cessation of phenobarbital injection. Arrows denote administration of phenobarbital. Changes in body weight (%) are in reference to the prewithdrawal level of body weight as 0%. Phenobarbital (40 mg/kg) and the vehicle control refer to 100% and 0% of suppression of withdrawal signs and relapse of the withdrawal signs , respectively. tration with PhB was followed by the relapse of the withdrawal signs in 8 to 12 hr. At this stage, severe signs such as clonic tonic convulsion began to recur in a few rats crops-administered with 20 mg/kg and in all rats of the 40 mg/kg group, proving that these dosages had almost completely maintained the PhB dependence.
The cross-administration with 5 and 10 mg/kg was followed by the relapse of less severe WSP than that with the higher dosages;
only moderate signs such as hyperirritability, ataxia and ear twitching relapsed.
WSP, with even anorexia, the mildest of all signs, recovering to almost the state before the withdrawal.
The WSP relapsing after cessation of the cross-administration were just similar in time course and severity to those from the control at 17 hr of PhB withdrawal.
In the control group, 1 out of 6 rats died of convulsions at 17 hr of PhB withdrawal, and another died of weakness 6 days later. In the group crcss-administered with barbital, 1 out of 6 rats died 7 days after the cessation of cross-administration (Fig. 3) . The treatment of barbital-admixed foods from immediately after PhB withdrawal likewise inhibited the WSP completely and was followed by the typical pattern of relapse of signs after its withdrawal (Fig. 3) . Pentobarbital:
This test drug, unlike barbital, failed to inhibit the severe with drawal signs unless a dose near to the sleep inducing dose to rats was administered. One hr after its cross-administration when the rats were still awake, tremor and systemic muscle twitching were seen in all rats, and clonic-tonic covulsion was seen in a few of them. The cross-administration with pento barbital at these doses resulted in the im Fig. 3 . Effects of cross-administration of barbital on body weight loss after phenobarbital withdrawal. Barbital was administered with both the injection method (from 17 hr to 48 hr after phenobarbital with drawal) and the drug-admixed foods method (immediately after phenobarbital withdrawal).
Short and long arrows during the substitution period denote the injection of 40 mg/kg and 80 mg/kg of barbital, respectively.
Percentage in parenthesis denotes maximally decreased rate of body weight of withdrawal control during the cross-administration period. mediate inhibition of these signs. However, due to its weak inhibiting action on anorexia, the food consumption remained low, resulting in less recovery of body weight loss. The cessation of cross-administration was there fore followed by mild WSP, with only clonic convulsion appearing sporadically. Moderate withdrawal signs relapsed on the whole.
Ethanol: Ethanol, like pentobarbital, did no inhibit WSP completely unless a marked behavioral depression was maintained. During the cross-administration with this durg, almost all the signs were inhibited with the rats in a coma-like state. However, in the mildly depressed stage exhibiting ptosis, many of them bit the penis which was erect. They showed a tendency to weakness due to bleeding from the penis and anorexia. Most of the rats died within a week following the cessation of the cross-administration due mainly to weakness (Fig. 4) .
In general, ethanol caused only partial inhibition of WSP, and a high dosage was necessary to inhibit severe grades of WSP, including convulsions.
Diazepam: The cross-administration of 20 to 40 mg/kg of diazepam inhibited severe grades of WSP such as muscle twitch, convulsions, hyperirritability, etc. and sedated the rats dose-relatedly.
However, this drug failed to inhibit the signs as completely as did barbital and nitrazepam, with some of the signs such as tremor. ataxia and anorexia persisting during the cross-administration. Especially, diasepam proved to be less inhibitory to anorexia, with the food con sumption of the cross-dosed group increasing only slightly over that of the withdrawal control group, and weight loss was more intense than with barbital and nitrazepam.
Relapse of convulsions was seen in a few rats and was only sporadic. Diazepam proved less contributory to the maintenance of PhB dependence than barbital and nitrazepam.
Nitrazepam: Almost all mild to severe WSP was inhibited with cross-administration with nitrazepam.
Rats ingested preferably nitrazepam-admixed food immediately after Fig. 4 . Effects of cross-administration of ethanol on body weight loss and food consumption after phenobarbital withdrawal. Ethanol (20%) was administered orally by a stomach tube (7 times, 17.5 g/kg in total). Short and long arrows during the cross-administration period denote injection of 1.75 g/kg and 3.5 g/kg of ethanol, respectively. Withdrawal signs after cessation of cross administration with nitrazepam was relapsed also dose-relatedly and was almost the same as those of the withdrawal control group observed from 0 hr to 48 hr after PhB withdrawal (Fig. 5) .
Meprobamate: Neither did meprobamate inhibit severe WSP unless a high dose was used to cause severe CNS depression such as loss of righting reflex. However, because it failed to recover and maintain normal food consumption and water intake, the rats tended to show weakness in general. Meprobamate proved to exert only partial suppression of WSP.
Methaqualone:
The cross-administration of 10 to 100 mg/kg of methaqualone suppressed WSP dose-relatedly.
The inhibition of the signs with 100 mg/kg of methaqualone. The mode of inhibition was also similar to that with nitrazepam which suppressed almost all the signs with such doses as to cause mild to moderate sedation. The relapse of the withdrawal signs came to its peak 48 hr after the withdrawal of the cross-administration. The relapse of signs of 100 mg/kg of methaqualone.
The suppression of the with drawal signs and the severity of relapse were intimately correlated (results not shown).
Other drugs: The cross-administration with chlorpromazine, diphenylhydantoin or me phenesin, for its sedative and systemic muscle relaxant actions, obviously suppressed the severe signs --especially, tonic convulsion. However, a high dose which seemed to be an overdosage in terms of general behaviors (e.g., hypothermia, dysuria, lying on the abdomen, etc.) was required to suppress the signs continuously. The cross-administration of a low dose was associated with frequent sudden occurrence of clonic convulsion, grand mal-type convulsion or hyperkinesia. Vocalization on touching, ataxia, piloerection, aggressiveness and tremor perisited even in the state of severe CNS depression. Anorexia was scarecely inhibited with any of these drugs. WSP were aggravated after the cessation of the cross-administration on the whole, with the rats tending to be more weakened due to prolonged duration of the signs (Figs. 6 and 7). Reserpine obviously intensified WSP as a whole especially withdrawal con vulsions remained likely to appear.
Clonidine at the doses causing severe CNS depression inhibited WSP such as hyperirritability, hyperreflexia, tremor, etc. However, this drug in no way inhibited anorexia. The cessation of this cross administration was followed by aggravation of the withdrawal signs on the whole, leading to retarded recovery. 
Discussion
The cross-physical dependence test has been widely used to evaluate the physical dependence liability of sedative-hypnotics because it can be done quickly and econo mically (6-11). However, it is sometime difficult to determine which type the test drugs belong to, the morphine or sedative hypnotics type. For this reason, both types of the cross-physical dependence test were required (15, 16). In the previous papers (15 17), we fully described the aspects of the physical dependence test of the morphine type drugs by the drug-admixed food (DAF) method (15-17). Here we have reported the method for the cross-physical dependence test on rats made phenobarbital -dependent by the DAF method and the method for the evaluation of the cross-dependence liability.
Observation of relapse of the withdrawal signs following cessation of the cross administration is a useful indicator to confirm the maintenance liability of barbiturate dependence with a test drug. In general, relapse of withdrawal signs after cross administration peaks at 48-72 hr after withdrawal of the test drugs (15, 16) . From the time course changes in withdrawal signs of long lasting barbiturates (e.g., PhB and barbital), most typical withdrawal signs, i.e., spontaneous clonic-tonic convulsions, were elicited and lasted from 24 to 48 hr after withdrawal from the drugs. After 48-72 hr, withdrawn rats showed gradual recovery from withdrawal convulsions (1, 2).
However, in the rats made very severely dependent on PhB in the present study, withdrawal convulsions were indeed elicited from 24 to 48 hr after withdrawal of PhB; but in many cases, some of the rats in the withdrawal-control group died immediately after convulsion (1), and other rats further showed long-lasting losses in body weight due to weakness that eventually lead to death (Figs. 1, 4, 5 and 7) . Therefore, long lasting loss in body weight observed later than 48-72 hr after the cessation of cross adrninistration is not a specific effect of the test drugs on PhB withdrawal signs. On the other hand, barbital-dependent rats (1, 15, 16, (18) (19) (20) in the same period of drug administration rarely died even after several time of convulsion, and loss in body weight recovered to pre-withdrawal levels on 7-8 days after the withdrawal of barbital. From these viewpoints, it is rational and accurate for evaluation of maintenance of barbiturate dependence to observe the relapse of the withdrawal signs within 48-72 hr after the cessation of cross-administration with the test drugs. The 13 drugs used both in this study and in the previous reports (15-20) could be classified into the following 3 types by both the mode of inhibition of WSP and the intensity of the relapsed signs within 48-72 hr after the cessation of the cross-administration with those test drugs (Fig. 8 These drugs practically do not inhibit WSP, and they do not recover food and water intake. No relapse of with drawal signs can be followed, and almost all rats recover from withdrawal signs 7-8 days after withdrawal from the test drugs.
Type III-b: Withdrawal-control rats made very severely dependent on barbiturates that elicit severe and durable clonic-tonic con vulsion. Some of the withdrawn rats die immediately after convulsions or long lasting weakness. In the animals cross-administered at high doses (e.g., severe CNS depression) of these drugs (Fig. 8, III) , weakness, the excretion of water-like feces, aggravation of general behavioral signs and longlasting loss in body weight can be observed. No relapse of withdrawal signs can be followed. These animals sometimes need more time for recovery from the withdrawal signs compared with that needed for control withdrawn animals (15, 16, 18) .
Abnormal metabolism of the brain mono amines is known to play an important role in the appearance of barbiturate withdrawal convulsion (19) (20) (21) . Norton (8) reported that reserpine aggravated barbital withdrawal convulsions (audiogenic seizure). More recently, we have reported that p-chloro phenylalanine intensified the withdrawal con vulsions and that the decrease in the brain catecholamines induced by a-methyl-p tyrosine or disulfiram resulted in the inhibition of the convulsions (22). Goldstein (10), on the other hand, studied the effect of monoamine-related compounds on alcohol withdrawal convulsions in mice. In a previous study (20), we found (3-adrenoceptor blockers, propranolol and pindolol, inhibit withdrawal convulsions of barbital suggesting that withdrawal convulsions might be derived from imbalance between the activities of noradrenergic and serotonergic neurons. However, mechanisms of various withdrawal signs other than convulsions has to be elucidated, and the role of monoamines in brain must await further studies.
From the viewpoint of drug dependence, there is a principle that withdrawal signs cannot be inhibited with any drug other than the drug depended upon. We believe it is most adequate to evaluate the effect of a test drug on withdrawal signs of barbiturate type drugs in terms of both the inhibition of withdrawal signs and maintenance of de pendence on the barbiturate.
In previous papers (17, 23), we described the results of the cross-physical dependence test using rats made more mildly dependent on phenobarbital than those used in this study. These rats exhibited only a few signs of mild hyperirritability. In mildly dependent animals, it is more difficult to discriminate the drugs apparently inhibiting withdrawal signs such as chlorpromazine, diphenyl hydantoin and clonidine from the drugs which have practically cross-physical de pendence to barbiturates. For the effective evaluation of cross-physical dependence liability to any test drug, it is important to investigate what kind of effect the drug exerts on the withdrawal signs close to those encountered clinically as in this study.
The results of this study are similar to the findings in dogs (6), monkeys (7) and humans (3, 24). The phenothiazine derivatives are often used clinically after alcohol with drawal. It is said that the gradual switchover of an antianxiety drug (e.g., diazepam) to neuroleptics is rather aimed at preventing the acquisition of dependence on the antianxiety drug rather than for the efficacy of neuro leptics on withdrawal syndromes (25). Also from the results of this study, chlorpromazine indeed inhibited part of the withdrawal signs, but the cessation of its cross-administration was associated with the retarded recovery of the signs and also with a tendency for the aggravation of signs due to weakness on the whole. Diphenylhydantoin, when adminis tered during PhB withdrawal, was found to have a similar action, which was well con sistent with the clinical findings (3).
It was further found that changes in the body weight of rats during and after cross administration of a test drug was useful as an index to evaluate the cross-physical dependence liability. 
